Copyright © 2021. Inderes Oyj. All rights reserved.

Nightingale’s H2 figures were weak throughout. The targets for the new fiscal year were also more conservative than our expectations and suggested that the potential for stronger growth is further down the road than we assumed. Therefore, we lowered our estimates considerably. In the short term, the high risks associated with the company's growth and valuation levels have realized and our views have been dramatically wrong. We still see preconditions for the company to achieve a significant commercial breakthrough with its technology in the future, but in the light of current information we do not expect any clear signs of this appearing in the next few years. We believe that the combination of slower growth and a highly cash-flow-negative development phase offers little critical short-term supporting points for valuation, especially in the current weakened capital market.  

Show your love by gifting this content to a fellow investor. As a Premium subscriber you can gift Premium-content to a free-user friend. Gift link:

Trade. (Nightingale Health)

Nightingalen liiketoiminta käynnistyi vuonna 2013. Yhtiön terveystietoalusta on luotu yhdistämällä kaksi vahvasti tieteellisesti todennettua kilpailuvalttia: Yhtiön kehittämä laaja-alainen verianalyysiteknologia ja kyky tunnistaa kokonaisvaltaisesti sairastumisriskejä. Yhtiön kehittämä laaja-alainen verianalyysiteknologiaprosessi alkaa verinäytteiden NMR -mittauksella, jossa käytetään skaalautuvaa laboratorioautomaatiota.